PEPG
Closed
Pepgen Ltd
1.09
-0.02 (-1.80%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 1.11
Day's Range: 1.05 - 1.12
Send
sign up or login to leave a comment!
When Written:
11.4
PepGen is a biotechnology company that is focused on developing transformative therapies for patients with neuromuscular diseases. The company is based in Durham, North Carolina and was founded in 2018 by Dr. Duke Engel and Dr. Michael Ehlers.
PepGen's technology platform is based on a proprietary peptide-based delivery system that enables the efficient delivery of therapeutic molecules to specific tissues and cells in the body. The company is currently developing a pipeline of therapies for various neuromuscular diseases, including Duchenne muscular dystrophy and spinal muscular atrophy.
PepGen has raised over $50 million in funding from investors including RA Capital Management, Samsara BioCapital, and Blackstone Life Sciences. The company has also entered into partnerships with several leading academic institutions and pharmaceutical companies to advance its research and development efforts.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
PepGen's technology platform is based on a proprietary peptide-based delivery system that enables the efficient delivery of therapeutic molecules to specific tissues and cells in the body. The company is currently developing a pipeline of therapies for various neuromuscular diseases, including Duchenne muscular dystrophy and spinal muscular atrophy.
PepGen has raised over $50 million in funding from investors including RA Capital Management, Samsara BioCapital, and Blackstone Life Sciences. The company has also entered into partnerships with several leading academic institutions and pharmaceutical companies to advance its research and development efforts.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








